In this episode, Brenda Martone, MSN, ANP-BC, AOCNP describes recent evidence on PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) and discusses best practices for incorporating PARP inhibitors into clinical practice. Topics include:<ul><li>An overview of the PROpel study of olaparib and the TRITON study of rucaparib</li><li>FDA-approved indications for olaparib and rucaparib</li><li>Genetic and molecular testing for BRCA1/2 and other HRR mutations</li><li>Managing adverse events associated with olaparib and rucaparib</li><li>Monitoring for and managing anemia</li><li>Gastrointestinal side effects</li><li>Fatigue</li><li>A look at the future of PARP inhibitors in mCRPC with combination approaches of AR-directed therapy and PARP inhibition</li></ul>Presenter: Brenda Martone, MSN, ANP-BC, AOCNP Nurse Practitioner Division of Genitourinary Oncology Northwestern Medicine Chicago, Illinois Link to full program: <a href="PCE.is/Onc22" target="_blank">PCE.is/Onc22</a>

Optimizing Immune Checkpoint Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer

Practicing Clinicians Exchange keeps advanced practice providers up to date with timely interviews from the front lines on current advances and best practices in medicine. Many of the podcasts are available for CE/CME credit.